IMMUNOLOGY2026™ Conference Recordings For Attendees-Immune organ tertiary lymphoid structures (TLSs) as a therapeutic strategy for solid tumors

Immune organ tertiary lymphoid structures (TLSs) as a therapeutic strategy for solid tumors

Video Transcription

Video Summary

The speaker presented an injectable tertiary lymphoid structure (TLS) therapy being developed for lung cancer. TLSs can activate B cells and T cells, produce antibodies, and promote long-term anti-tumor immunity. Using a lung cancer-on-chip model, the team found that “hot” tumors induced stronger TLS formation, cytokine responses, and cancer cell killing than “cold” tumors. In humanized and syngeneic mouse models, peritumoral injection generated TLS-like structures and reduced tumor growth, with improved survival in mice. The study suggests injectable TLS therapeutics may boost anti-tumor immunity in supportive tumor microenvironments.

Meta Tag

Date April 19, 2026 9:00 AM - 9:15 AM

Room 156

Session Immune Cells in the Tumor Microenvironment II

Speaker Sudip Paudel

Track Tumor Immunology: Cellular Responses and Tumor Microenvironment (TIME)

Year 2026

Keywords

tertiary lymphoid structures

lung cancer

anti-tumor immunity

tumor microenvironment

injectable therapy

April 19, 2026 9:00 AM - 9:15 AM

156

Immune Cells in the Tumor Microenvironment II

Sudip Paudel

Tumor Immunology: Cellular Responses and Tumor Microenvironment (TIME)

2026